COPD Assessment Test

Abstract

The COPD Assessment Test (CAT) is a concise, 8-item, patient-completed health status questionnaire designed to measure the daily impact of COPD (Chronic Obstructive Pulmonary Disease) on an individual’s life. It provides a simple, numerical score ranging from 0 to 40. Higher scores indicate a greater severity of symptoms and a more significant negative impact on the patient’s overall well-being and Health-Related Quality of Life (HRQoL).

Keywords

COPD, CAT, Health Status, Quality of Life, Lung Disease, Respiratory Assessment, Symptom Burden, Psychometric.

Authors

Jones et al. (2009)

Purpose

The primary purpose of the CAT is to provide clinicians and patients with a quick, standardized method for assessing the severity and burden of COPD symptoms in routine clinical practice. Unlike lengthy questionnaires, the CAT is designed for ease of administration and interpretation, facilitating shared decision-making regarding treatment escalation or de-escalation based on the patient’s subjective experience.

It is widely used to monitor changes in a patient’s health status over time, particularly in response to pharmacological or non-pharmacological interventions. The scale aims to capture the patient’s subjective experience across various domains affected by the disease, including physical function and emotional well-being.

Construct

The CAT measures the construct of COPD-specific health status or symptom burden, focusing intensely on the subjective impact of the disease rather than purely objective clinical metrics like Forced Expiratory Volume in 1 second (FEV1). The 8 items cover a wide array of symptoms and functional limitations commonly experienced by individuals with COPD.

The domains assessed include cough and phlegm production, chest tightness, breathlessness during activity, confidence in leaving home, sleep quality, and energy levels. Collectively, these items quantify the impact of the disease on daily functioning and Health-Related Quality of Life, serving as a patient-reported outcome measure (PROM).

Validity

The CAT demonstrates strong Validity across various international studies. Concurrent validity has been robustly established through high correlations with the St. George’s Respiratory Questionnaire (SGRQ), which is considered the gold standard for measuring health status in COPD. Studies consistently show correlations (r > 0.60) between the total CAT score and the SGRQ total score, confirming that they measure similar concepts.

Furthermore, the scale exhibits excellent known-groups validity, reliably distinguishing between patients categorized into different severity grades (e.g., GOLD groups A, B, C, and D). The CAT is also highly sensitive to change, demonstrating strong responsiveness, which is crucial for monitoring treatment efficacy and capturing clinically important deterioration or improvement in longitudinal studies.

Reliability

The Reliability of the CAT is generally high, confirming its stability and internal consistency as a measurement tool. Internal consistency, typically assessed using Cronbach’s alpha, consistently exceeds 0.85 across diverse patient populations, suggesting that the 8 items reliably measure the same underlying construct of symptom impact.

Test-retest reliability has also been confirmed through studies administered to stable patients over short time intervals (e.g., 2 to 4 weeks), demonstrating score stability when the patient’s clinical status has not changed. The minimal clinically important difference (MCID) for the CAT is established at 2 points, providing clinicians with a benchmark for determining meaningful clinical improvement or deterioration.

Factor Analysis

Initial psychometric analyses conducted during the scale’s development, along with subsequent validation studies, generally support a unidimensional structure for the CAT. This means the scale is primarily intended to measure a single overarching concept: the overall burden and impact of COPD on the patient’s life.

While some exploratory factor analyses in specific cultural or clinical subgroups have suggested potential two-factor models (often dividing items into a “symptom/physical” factor and an “impact/emotional” factor), the developers and widespread clinical practice prioritize the interpretation of the single total score (0–40). This emphasis reinforces its intended use as a simple, holistic, and clinically actionable assessment tool.

Instrument

Test Type: Questionnaire (Patient-Reported Outcome Measure)

Format: 8 items, scored on a 6-point Likert scale (ranging from 0 to 5) for each item, resulting in a total score range of 0 to 40. The administration time is typically less than two minutes.

Language Available: Developed in English, validated and widely available in numerous languages globally, including Dutch (as per source), Spanish, French, German, and Chinese.

Population Group: Patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD).

Age Group: Adults and Elderly (Volwassenen, Ouderen).

Population Details: Applicable across the spectrum of COPD severity (mild to very severe) and various clinical settings (primary care, specialist clinics, research). It assesses functions related to Activities, Mental functions, Sensorische functions and pain, targeting the Thorax/abdomen/organs and related circulatory and respiratory system issues.

Test Methodology: Self-administered paper or digital questionnaire. The original explanatory form (PDF) can be downloaded here: CAT-form.pdf

Keywords

Assessment, Respiratory Disease, Patient-Reported Outcome (PRO), SGRQ, Responsiveness, Validity, Health Questionnaire.

Authors

Author ORCID Identifier: N/A (Information not provided in source)

Affiliation Email addresses: N/A (Information not provided in source)

Correspondence Address: Refer to the official CAT website for licensing and correspondence details: http://www.catestonline.org/english/index_BelgiumNL.htm

Permissions & Fee and Test Year

The COPD Assessment Test was officially introduced and published in 2009 by Jones et al. It is often provided free of charge for non-commercial clinical use, especially for individual patient care. However, specific licensing agreements are required for commercial use, integration into electronic health records, or use in large-scale clinical trials.

Users are advised to consult the official website linked above for current permissions, translations, and any potential fee structures associated with large-scale or commercial deployment of the instrument.

Reference’s

• Jones, P. W., Harding, G., Berry, P., Wiklund, I., Chen, W. H., & Kline Leidy, N. (2009). Development and first validation of the COPD Assessment Test (CAT). European Respiratory Journal, 34(3), 648–654.

• Official CAT Website: http://www.catestonline.org/english/index_BelgiumNL.htm

Items of the COPD Assessment Test

IMPORTANT: The following scale items must be preserved in their original language and must not be changed in any way.

The specific items comprising the 8-item COPD Assessment Test were not detailed in the source material provided. The CAT measures patient experience across domains including cough, phlegm production, chest tightness, breathlessness going up hills/stairs, limitations in activities at home, confidence, sleep quality, and energy levels.